Ryan & Maniskas, LLP ( www.rmclasslaw.com/cases/clda) is investigating potential claims against the board of directors of Clinical Data, Inc. ("Clinical Data" or the "Company") (NASDAQ: CLDA) concerning possible breaches of fiduciary duty and other violations of law related to the Company’s efforts to sell Clinical Data to Forest Laboratories, Inc. in a transaction with a value of approximately $1.2 billion. Our investigation concerns possible breaches of fiduciary duty and other violations of law related to approval of the transaction by Company’s board of directors; in particular, whether the Company undertook a fair process to obtain fair consideration for all shareholders of Clinical Data. For more information regarding our investigation, please contact Ryan & Maniskas, LLP (Richard A. Maniskas, Esquire) toll-free at (877) 316-3218 or by email at email@example.com or visit: www.rmclasslaw.com/cases/clda. Under the terms of the definitive agreement, Clinical Data shareholders would receive a cash payment of $30.00 per share for each share they own of the Company’s stock, plus contingent consideration of up to $6.00 per share that may be paid upon achievement of certain commercial milestones related to Viibryd. If you own shares of Clinical Data and would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (877) 316-3218 or to sign up online, visit: www.rmclasslaw.com/cases/clda. You may also email Mr. Maniskas at firstname.lastname@example.org. For more information about class action cases in general, please visit our website: www.rmclasslaw.com. Ryan & Maniskas, LLP is a national shareholder litigation firm. Ryan & Maniskas, LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.
Cheng Yi Liang, a chemist with the U.S. Food and Drug Administration, was charged by the Securities and Exchange Commission with insider trading on information regarding upcoming FDA drug approval decisions on Tuesday.